Evaluate Vantage COVID-19 Report

Biopharma and Medtech are leading the fight against COVID-19, but are not immune from the significant economic impact of the pandemic.

The new Evaluate Vantage COVID-19 Report examines biopharma’s progress in identifying which treatments and vaccines are of most interest in the fight against the virus.

It also examines the effect the pandemic is having on the sector, including share price declines, potential financial implications of disruption and cost of delays, as well as the deals being triggered by the crisis.

Download your copy of the Evaluate Vantage COVID-19 Report to understand the coronavirus’s impact on biopharma, and the sector’s response.

Download Your Copy

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

  • Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
  • Aenean commodo ligula eget dolor.
  • Aenean massa consequat massa quis enim. nenatis vitae, justo

Lorem ipsum dolor sit amet

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

2020Absolute market cap gains and losses, by size bracket

Key Report Highlights

  • Understand biopharma and medtech’s response: find out where development of investigational treatments stands, including the leading clinical trials of vaccines and potential treatments, as well as the logic behind the various approaches
  • Assess the impact on biopharma: discover which new deals and collaborations have been forged in response to the pandemic, as well as the damage to share prices, clinical trial delays and the potential blockbuster drugs that may be under threat
  • Compare with thstorical precedents: examine sales of previous antivirals and pandemic vaccines to understand the potential of COVID-19 treatments, as well as the estimated costs of their development and which vaccine producers have the infrastructure to meet global demand

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Lorem ipsum dolor

Aenean commodo ligula eget dolor.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. nenatis vitae, justo.

Mauris Interdum Vehicula

Lorem ipsum dolor sit amet, consectetuer adipiscing elit.

Mauris Interdum Vehicula

Lorem ipsum dolor sit amet, consectetuer adipiscing elit.

Lorem ipsum

Download our white papers

Three resources for the professionally curious

Schedule EvaluatePharma Vision demo >
Stimulus      
Daily news with expert analysis
Interviews with industry leaders
Company & product events coverage
Response      
Consensus forecasts to 2024  
Archived consensus forecasts  
Sales by indication  
Therapy area, mechanism of action, and other classifications  
Licensing deals, M&A, venture financing and IPOs  
Orphan drugs and biosimilars analysis  
Success rate benchmarks (PTRS)    
Time-in-phase benchmarks by indication    
Comprehensive product and trial level R&D costs    
Clinical trials design and outcomes    
Net Present Value calculator    
Calendar of market events and catalysts    

What our readers say